Carl Kraus

Carl Kraus

Director Técnico/Científico/I+D en AQUESTIVE THERAPEUTICS, INC. .

Fortuna: 1 M $ al 30/04/2024

Health Technology
Commercial Services
Consumer Services

Perfil

Carl N.
Kraus
was the founder of Arrevus, Inc. founded in 2015, where he held the titles of Chairman, President & Chief Executive Officer from 2017 to 2021.
Currently, he is the Medical Director at i3 Research, Inc. and the Chief Medical Officer at Aquestive Therapeutics, Inc. since 2023.
Previously, he served as the Chief Medical Officer at Idera Pharmaceuticals, Inc. and Resilience Government Services, Inc. He was also the Chief Medical Officer at Aceragen, Inc. from 2021 to 2023.
Dr. Kraus received his undergraduate degree from Washington University School of Medicine.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
07/03/2024 262 500 ( 0.29% ) 1 M $ 30/04/2024
17/01/2023 0 ( -.--% ) - $ 31/07/2023

Cargos activos de Carl Kraus

EmpresasCargoInicio
AQUESTIVE THERAPEUTICS, INC. Director Técnico/Científico/I+D 26/06/2023
Director Técnico/Científico/I+D -
Todos los cargos activos de Carl Kraus

Antiguos cargos conocidos de Carl Kraus.

EmpresasCargoFin
ACERAGEN, INC. Director Técnico/Científico/I+D 30/04/2023
Director Ejecutivo 31/10/2021
Director Técnico/Científico/I+D -
Director Técnico/Científico/I+D -
Ver el detalle de la experiencia de Carl Kraus.

Formación de Carl Kraus.

Washington University School of Medicine Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Carl Kraus.

Relaciones

23

Relaciones de 1er grado

7

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas1
AQUESTIVE THERAPEUTICS, INC.

Health Technology

Empresas privadas5

Commercial Services

Health Technology

Health Technology

Health Technology

Aceragen, Inc.

Ver las conexiones de la empresa
-40% Prolongación excepcional: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA